Journal article 1285 views
Impact of glucose levels on advanced glycation end products in hemodialysis
Hemodialysis International, Volume: 11, Issue: 3, Pages: 278 - 285
Swansea University Author: Ruth Godfrey
Full text not available from this repository: check for access using links below.
DOI (Published version): 10.1111/j.1542-4758.2007.00180.x
Abstract
The current obesity epidemic throughout the western world has resulted in a considerable increase in the condition Type II diabetes mellitus. Recently, the World Health Organization has predicted that the global prevalence of Type II will increase from 175 million patients in 2003 to over 350 millio...
Published in: | Hemodialysis International |
---|---|
ISSN: | 1492-7535 1542-4758 |
Published: |
Wiley
2007
|
Online Access: |
Check full text
|
URI: | https://cronfa.swan.ac.uk/Record/cronfa6121 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
first_indexed |
2013-07-23T11:54:28Z |
---|---|
last_indexed |
2020-06-19T12:17:15Z |
id |
cronfa6121 |
recordtype |
SURis |
fullrecord |
<?xml version="1.0"?><rfc1807><datestamp>2020-06-19T12:06:54.1517428</datestamp><bib-version>v2</bib-version><id>6121</id><entry>2011-10-01</entry><title>Impact of glucose levels on advanced glycation end products in hemodialysis</title><swanseaauthors><author><sid>b7e381bae1b3f74a3521be56c9b2d2ae</sid><ORCID>0000-0002-8830-3625</ORCID><firstname>Ruth</firstname><surname>Godfrey</surname><name>Ruth Godfrey</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2011-10-01</date><deptcode>BMS</deptcode><abstract>The current obesity epidemic throughout the western world has resulted in a considerable increase in the condition Type II diabetes mellitus. Recently, the World Health Organization has predicted that the global prevalence of Type II will increase from 175 million patients in 2003 to over 350 million by 2030. One of the major consequences of this disorder is renal failure, which presents itself as chronic kidney disease, and can progress to end-stage renal disease. Once diagnosed, patients are generally treated using dialysis due to a shortage of kidney donors. The fundamental process of dialysis still requires improvement because the survival rate of these patients is relatively poor. This has resulted in considerable research into improvements in hemodialysis membranes, and the challenge to find more suitable marker(s) in assessing the efficacy of the dialysis process. A class of compounds highlighted as a possible accumulative toxin is advanced glycation end products or AGEs. This is an article regarding the impact of hemodialysis and hemodiafiltration on glucose and AGE levels within the body and the consequences of a chronic hyperglycemic condition. It also highlights the negative aspects of using dextrose in conventional dialysis solutions (an area that has already been identified by peritoneal dialysis clinicians as problematic). The review concludes by suggesting several possible topics of future research.</abstract><type>Journal Article</type><journal>Hemodialysis International</journal><volume>11</volume><journalNumber>3</journalNumber><paginationStart>278</paginationStart><paginationEnd>285</paginationEnd><publisher>Wiley</publisher><issnPrint>1492-7535</issnPrint><issnElectronic>1542-4758</issnElectronic><keywords/><publishedDay>31</publishedDay><publishedMonth>12</publishedMonth><publishedYear>2007</publishedYear><publishedDate>2007-12-31</publishedDate><doi>10.1111/j.1542-4758.2007.00180.x</doi><url>http://onlinelibrary.wiley.com/doi/10.1111/j.1542-4758.2007.00180.x/full</url><notes/><college>COLLEGE NANME</college><department>Biomedical Sciences</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>BMS</DepartmentCode><institution>Swansea University</institution><apcterm/><lastEdited>2020-06-19T12:06:54.1517428</lastEdited><Created>2011-10-01T00:00:00.0000000</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Medicine</level></path><authors><author><firstname>Ruth</firstname><surname>Godfrey</surname><orcid>0000-0002-8830-3625</orcid><order>1</order></author></authors><documents/><OutputDurs/></rfc1807> |
spelling |
2020-06-19T12:06:54.1517428 v2 6121 2011-10-01 Impact of glucose levels on advanced glycation end products in hemodialysis b7e381bae1b3f74a3521be56c9b2d2ae 0000-0002-8830-3625 Ruth Godfrey Ruth Godfrey true false 2011-10-01 BMS The current obesity epidemic throughout the western world has resulted in a considerable increase in the condition Type II diabetes mellitus. Recently, the World Health Organization has predicted that the global prevalence of Type II will increase from 175 million patients in 2003 to over 350 million by 2030. One of the major consequences of this disorder is renal failure, which presents itself as chronic kidney disease, and can progress to end-stage renal disease. Once diagnosed, patients are generally treated using dialysis due to a shortage of kidney donors. The fundamental process of dialysis still requires improvement because the survival rate of these patients is relatively poor. This has resulted in considerable research into improvements in hemodialysis membranes, and the challenge to find more suitable marker(s) in assessing the efficacy of the dialysis process. A class of compounds highlighted as a possible accumulative toxin is advanced glycation end products or AGEs. This is an article regarding the impact of hemodialysis and hemodiafiltration on glucose and AGE levels within the body and the consequences of a chronic hyperglycemic condition. It also highlights the negative aspects of using dextrose in conventional dialysis solutions (an area that has already been identified by peritoneal dialysis clinicians as problematic). The review concludes by suggesting several possible topics of future research. Journal Article Hemodialysis International 11 3 278 285 Wiley 1492-7535 1542-4758 31 12 2007 2007-12-31 10.1111/j.1542-4758.2007.00180.x http://onlinelibrary.wiley.com/doi/10.1111/j.1542-4758.2007.00180.x/full COLLEGE NANME Biomedical Sciences COLLEGE CODE BMS Swansea University 2020-06-19T12:06:54.1517428 2011-10-01T00:00:00.0000000 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Medicine Ruth Godfrey 0000-0002-8830-3625 1 |
title |
Impact of glucose levels on advanced glycation end products in hemodialysis |
spellingShingle |
Impact of glucose levels on advanced glycation end products in hemodialysis Ruth Godfrey |
title_short |
Impact of glucose levels on advanced glycation end products in hemodialysis |
title_full |
Impact of glucose levels on advanced glycation end products in hemodialysis |
title_fullStr |
Impact of glucose levels on advanced glycation end products in hemodialysis |
title_full_unstemmed |
Impact of glucose levels on advanced glycation end products in hemodialysis |
title_sort |
Impact of glucose levels on advanced glycation end products in hemodialysis |
author_id_str_mv |
b7e381bae1b3f74a3521be56c9b2d2ae |
author_id_fullname_str_mv |
b7e381bae1b3f74a3521be56c9b2d2ae_***_Ruth Godfrey |
author |
Ruth Godfrey |
author2 |
Ruth Godfrey |
format |
Journal article |
container_title |
Hemodialysis International |
container_volume |
11 |
container_issue |
3 |
container_start_page |
278 |
publishDate |
2007 |
institution |
Swansea University |
issn |
1492-7535 1542-4758 |
doi_str_mv |
10.1111/j.1542-4758.2007.00180.x |
publisher |
Wiley |
college_str |
Faculty of Medicine, Health and Life Sciences |
hierarchytype |
|
hierarchy_top_id |
facultyofmedicinehealthandlifesciences |
hierarchy_top_title |
Faculty of Medicine, Health and Life Sciences |
hierarchy_parent_id |
facultyofmedicinehealthandlifesciences |
hierarchy_parent_title |
Faculty of Medicine, Health and Life Sciences |
department_str |
Swansea University Medical School - Medicine{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Medicine |
url |
http://onlinelibrary.wiley.com/doi/10.1111/j.1542-4758.2007.00180.x/full |
document_store_str |
0 |
active_str |
0 |
description |
The current obesity epidemic throughout the western world has resulted in a considerable increase in the condition Type II diabetes mellitus. Recently, the World Health Organization has predicted that the global prevalence of Type II will increase from 175 million patients in 2003 to over 350 million by 2030. One of the major consequences of this disorder is renal failure, which presents itself as chronic kidney disease, and can progress to end-stage renal disease. Once diagnosed, patients are generally treated using dialysis due to a shortage of kidney donors. The fundamental process of dialysis still requires improvement because the survival rate of these patients is relatively poor. This has resulted in considerable research into improvements in hemodialysis membranes, and the challenge to find more suitable marker(s) in assessing the efficacy of the dialysis process. A class of compounds highlighted as a possible accumulative toxin is advanced glycation end products or AGEs. This is an article regarding the impact of hemodialysis and hemodiafiltration on glucose and AGE levels within the body and the consequences of a chronic hyperglycemic condition. It also highlights the negative aspects of using dextrose in conventional dialysis solutions (an area that has already been identified by peritoneal dialysis clinicians as problematic). The review concludes by suggesting several possible topics of future research. |
published_date |
2007-12-31T03:07:33Z |
_version_ |
1763749766958678016 |
score |
11.037581 |